methocarbamol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1747 532-03-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methocarbamol
  • glycerylguaiacolate carbamate
  • guaiacol glyceryl ether carbamate
  • guaiphenesin carbamate
  • guaiamar carbamate
A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
  • Molecular weight: 241.24
  • Formula: C11H15NO5
  • CLOGP: 0.15
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 91.01
  • ALOGS: -1.76
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
3 g P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 16, 1957 FDA AUXILIUM PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Necrosis ischaemic 63.58 12.19 20 17176 825 46668041
Pneumonia streptococcal 53.46 12.19 21 17175 1674 46667192
Muscle spasms 50.37 12.19 128 17068 122985 46545881
Beta haemolytic streptococcal infection 47.88 12.19 20 17176 1869 46666997
Acquired haemophilia 45.84 12.19 16 17180 915 46667951
Completed suicide 44.20 12.19 136 17060 145784 46523082
Gallbladder polyp 40.90 12.19 14 17182 755 46668111
Multiple drug therapy 38.58 12.19 14 17182 897 46667969
Diabetes mellitus inadequate control 31.28 12.19 31 17165 13183 46655683
Migraine 25.74 12.19 70 17126 69956 46598910
Drug hypersensitivity 24.73 12.19 164 17032 243661 46425205
Spinal operation 23.24 12.19 18 17178 5522 46663344
Fibromyalgia 22.87 12.19 45 17151 36418 46632448
Analgesic drug level increased 22.50 12.19 11 17185 1483 46667383
Rheumatoid arthritis 22.05 12.19 34 17162 240181 46428685
Treatment failure 21.72 12.19 4 17192 93083 46575783
Anxiety 21.30 12.19 127 17069 181830 46487036
Pain 20.69 12.19 267 16929 476681 46192185
Neutropenia 20.22 12.19 14 17182 143190 46525676
Withdrawal syndrome 18.82 12.19 28 17168 18106 46650760
Amnesia 18.81 12.19 45 17151 41586 46627280
Back pain 18.76 12.19 137 17059 209902 46458964
Road traffic accident 18.32 12.19 32 17164 23659 46645207
Hypertension 18.06 12.19 129 17067 196227 46472639
Cardiac failure 17.48 12.19 4 17192 79944 46588922
Maternal exposure during pregnancy 17.38 12.19 8 17188 102541 46566325
Infusion related reaction 16.99 12.19 8 17188 101200 46567666
Febrile neutropenia 16.64 12.19 7 17189 94620 46574246
Contusion 16.57 12.19 70 17126 87417 46581449
Intervertebral disc protrusion 16.35 12.19 28 17168 20377 46648489
Thyroiditis chronic 15.90 12.19 3 17193 12 46668854
Illness 15.85 12.19 21 17175 12203 46656663
Livedo reticularis 15.76 12.19 10 17186 2234 46666632
Blood pressure inadequately controlled 15.68 12.19 13 17183 4393 46664473
Somnolence 15.67 12.19 105 17091 156416 46512450
Back disorder 15.55 12.19 18 17178 9123 46659743
Exercise tolerance decreased 15.24 12.19 13 17183 4564 46664302
Respiratory arrest 14.68 12.19 36 17160 33780 46635086
Depression 14.63 12.19 110 17086 169994 46498872
Fall 14.55 12.19 185 17011 328912 46339954
Drug intolerance 14.27 12.19 20 17176 147029 46521837
Oesophagitis 14.06 12.19 21 17175 13630 46655236
Surgery 13.97 12.19 32 17164 28753 46640113
Loss of consciousness 13.59 12.19 77 17119 108161 46560705
Therapeutic reaction time decreased 13.55 12.19 7 17189 1061 46667805
Exposure during pregnancy 13.48 12.19 12 17184 108200 46560666
Therapy cessation 13.36 12.19 30 17166 26599 46642267
Gastrointestinal haemorrhage 13.17 12.19 6 17190 77367 46591499
Pre-existing condition improved 12.92 12.19 14 17182 6598 46662268
Off label use 12.64 12.19 85 17111 379756 46289110
Pancytopenia 12.43 12.19 8 17188 85050 46583816
Intervertebral disc disorder 12.30 12.19 11 17185 4111 46664755

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug dependence 53.95 14.73 44 7522 21251 29923661
Victim of child abuse 39.24 14.73 10 7556 280 29944632
Phonophobia 37.26 14.73 8 7558 103 29944809
Depression 30.26 14.73 69 7497 90368 29854544
Respiratory depression 23.46 14.73 21 7545 11482 29933430
Back pain 22.67 14.73 67 7499 102529 29842383
Child abuse 22.12 14.73 6 7560 215 29944697
Poisoning deliberate 21.13 14.73 15 7551 5889 29939023
Suicide attempt 20.82 14.73 35 7531 36662 29908250
Memory impairment 20.48 14.73 35 7531 37139 29907773
Back injury 20.05 14.73 12 7554 3533 29941379
Spinal operation 19.06 14.73 10 7556 2286 29942626
Back disorder 18.66 14.73 14 7552 5980 29938932
Product prescribing error 18.54 14.73 22 7544 16711 29928201
Serum procollagen type III N-terminal propeptide increased 17.27 14.73 4 7562 74 29944838
Post-traumatic neck syndrome 15.60 14.73 4 7562 115 29944797
Anxiety 15.56 14.73 54 7512 89817 29855095
Insomnia 15.23 14.73 55 7511 93281 29851631
Suicidal ideation 14.87 14.73 30 7536 36084 29908828
Pain 14.78 14.73 84 7482 172557 29772355

Pharmacologic Action:

SourceCodeDescription
ATC M03BA03 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Carbamic acid esters
ATC M03BA53 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Carbamic acid esters
ATC M03BA73 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Carbamic acid esters
FDA PE N0000175730 Centrally-mediated Muscle Relaxation
FDA EPC N0000175737 Muscle Relaxant
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:51371 muscle relaxants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Spasticity indication 221360009
Muscle Spasm with Pain indication
Tetanus Adjunct Treatment indication
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Gastrointestinal ulcer contraindication 40845000
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Acute nephropathy contraindication 58574008
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Anemia due to enzyme deficiency contraindication 111577008
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001
Acute erosive gastritis contraindication 444926003

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 1 Enzyme INHIBITOR Ki 7.60 IUPHAR CHEMBL

External reference:

IDSource
4017879 VUID
N0000146232 NUI
D00402 KEGG_DRUG
4017879 VANDF
C0025659 UMLSCUI
CHEBI:6832 CHEBI
CHEMBL1201117 ChEMBL_ID
D008721 MESH_DESCRIPTOR_UI
DB00423 DRUGBANK_ID
6829 IUPHAR_LIGAND_ID
776 INN_ID
125OD7737X UNII
4107 PUBCHEM_CID
6845 RXNORM
5075 MMSL
988 MMSL
d00965 MMSL
001669 NDDF
387486000 SNOMEDCT_US
83973001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0143-1290 TABLET 500 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0143-1292 TABLET 750 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0440-1740 TABLET 500 mg ORAL ANDA 23 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0517-1825 INJECTION 100 mg INTRAMUSCULAR ANDA 20 sections
ROBAXIN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6103 INJECTION 100 mg INTRAMUSCULAR NDA 22 sections
ROBAXIN HUMAN PRESCRIPTION DRUG LABEL 1 0641-6217 INJECTION 100 mg INTRAMUSCULAR NDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7057 TABLET 500 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7058 TABLET 750 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10135-664 TABLET, FILM COATED 500 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10135-665 TABLET, FILM COATED 750 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-259 TABLET 750 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-464 TABLET 750 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-622 TABLET 750 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-773 TABLET 500 mg ORAL ANDA 22 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 10544-956 TABLET 750 mg ORAL ANDA 23 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 16590-147 TABLET 500 mg ORAL ANDA 21 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 16590-148 TABLET 750 mg ORAL ANDA 21 sections
ROBAXIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-981 TABLET, FILM COATED 750 mg ORAL NDA 11 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 17511-505 TABLET, FILM COATED 500 mg ORAL ANDA 20 sections
METHOCARBAMOL HUMAN PRESCRIPTION DRUG LABEL 1 17511-506 TABLET, FILM COATED 750 mg ORAL ANDA 20 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 21695-078 TABLET 500 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 21695-079 TABLET 750 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 25021-675 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 23 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 31722-533 TABLET 500 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 31722-534 TABLET 750 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 33261-072 TABLET 750 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 33261-130 TABLET 500 mg ORAL ANDA 21 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 35561-211 TABLET, COATED 750 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 35561-212 TABLET, COATED 500 mg ORAL ANDA 19 sections
Methocarbamol HUMAN PRESCRIPTION DRUG LABEL 1 35573-413 TABLET, COATED 500 mg ORAL ANDA 19 sections